论文部分内容阅读
目的观察依托泊苷、亚叶酸钙、5氟尿嘧啶(ELF方案)联合奥沙利铂治疗晚期胃癌的临床疗效,探讨其临床应用价值。方法选取2010年2月至2011年9月收治的64例晚期胃癌患者,随机分为对照组(32例)和观察组(32例)。对照组患者单纯采用ELF方案进行治疗,观察组患者在此基础上联合奥沙利铂进行治疗,3周为1个疗程,共进行2个疗程治疗。观察并比较两组患者的临床疗效及不良反应发生情况。结果观察组患者总有效率为50.0%(16/32),明显高于对照组的28.1%(9/32),两组比较差异有统计学意义(P<0.05)。观察组患者不良反应较轻,主要为骨髓抑制(8例)、神经感觉异常(8例)及胃肠道反应(6例),明显低于对照组的17例、15例和18例,两组比较差异有统计学意义(P<0.05)。结论 ELF方案联合奥沙利铂治疗晚期胃癌疗效显著,不良反应小,可作为临床治疗晚期胃癌的首选方案,值得推广和应用。
Objective To observe the clinical efficacy of etoposide, leucovorin and 5-fluorouracil (ELF) in combination with oxaliplatin in the treatment of advanced gastric cancer and to explore its clinical value. Methods Sixty-four patients with advanced gastric cancer who were admitted from February 2010 to September 2011 were randomly divided into control group (32 cases) and observation group (32 cases). Patients in the control group were treated with ELF regimen alone. Patients in the observation group were treated with oxaliplatin on this basis. One course of treatment was given for 3 weeks and a total of 2 courses of treatment were performed. The clinical efficacy and adverse reactions of the two groups were observed and compared. Results The total effective rate in the observation group was 50.0% (16/32), which was significantly higher than that in the control group (28.1%, 9/32). There was significant difference between the two groups (P <0.05). The patients in the observation group had less adverse reactions, including myelosuppression (8 cases), neurosensory abnormalities (8 cases) and gastrointestinal reactions (6 cases), which were significantly lower than those in the control group (17 cases, 15 cases and 18 cases, two cases) The difference was statistically significant (P <0.05). Conclusion The combination of ELF regimen and oxaliplatin in the treatment of advanced gastric cancer has obvious curative effect and small adverse reactions and can be used as the first choice for clinical treatment of advanced gastric cancer. It is worthy of promotion and application.